Solo Pace announced today that it received FDA clearance for its SoloPace Control System for temporary pacing in TAVR ...

Solo Pace Incorporated, an emerging medical technology company, announced both FDA Clearance and First-In-Human use of their SoloPace Control System for temporary pacing in Transcatheter Aortic Valve ...

With surveillance, conversion to acute valve syndrome happened frequently and was linked to worse clinical outcomes.

BACKGROUND: Real-world low-risk transcatheter aortic valve replacement (TAVR) outcomes in the United States have not been assessed comprehensively versus pivotal trials, which is a key component of ...

The first human TAVR was performed by Dr. Cribier in 2002 ... and major vascular complications such as cardiac perforation or arterial dissection. Potential long term harms include death ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Indian-made ...

Patients with severe aortic stenosis at low surgical risk who underwent supra-annular, self-expanding Evolut transcatheter aortic valve replacement (TAVR) had similar rates of death or disabling ...

Medtronic, Abbott and Boston Scientific had updates on their devices used in heart valve disease treatment at the event.

Transcatheter aortic valve implantation has ... with the potential for unexpected complications always readily apparent. For this reason, the importance of specific training, such as that provided ...

TAVR involves inserting a thin flexible tube ... that requires timely diagnosis and treatment to prevent severe complications ...

Data shows, versus surgery, the Evolut™ transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years ...